iabetes mellitus is highly prevalent and attributed to the majority of cardiovascular mortality and morbidity worldwide, representing a huge burden on health care and social economy.
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iabetes mellitus is highly prevalent and attributed to the majority of cardiovascular mortality and morbidity worldwide, representing a huge burden on health care and social economy. 1 Diabetic comorbidities such as hypertension and dyslipidemia substantially increase mortality risk. [2] [3] [4] It has been consistently shown that blood pressure (BP)-lowering therapy leads to a significant reduction in cardiovascular events (CVEs) and death in individuals with both diabetes mellitus and hypertension. 5 However, a J-curve phenomenon was observed in the Framingham Heart Study 6 and several randomized controlled trials, [7] [8] [9] [10] [11] resulting in debate as to the meaning of this finding. 12 In these studies, low BP (eg, systolic BP [SBP] <130 mm Hg or diastolic BP [DBP] <70 mm Hg) conferred increased risks of CVEs and all-cause mortality in individuals with diabetes mellitus. 12 It is worth noting that these randomized controlled trials for the administration of antihypertensive drugs restricted prescriptions mostly to diabetic people with hypertension or at a high risk of clinical/subclinical atherosclerotic diseases. It remains unknown whether this J-curve phenomenon exists in untreated normotensive diabetics.
The Eighth Joint National Committee recommended a goal SBP <140 mm Hg and a goal DBP <90 mm Hg in adults with both diabetes mellitus and hypertension. These thresholds were the same as for the general hypertensive population aged <60 years because solid evidence for diabetic people is scanty. 13 The panel also did not address the SBP range of 120 to 139 mm Hg or DBP of 80 to 89 mm Hg, which was previously called prehypertension in the seventh Joint National Committee.
Recently, the Systolic Blood Pressure Intervention Trial (SPRINT) reported encouraging results regarding a protection from CVEs with intensive BP control (a target SBP <120 mm Hg) when compared with standard BP control (a target SBP <140 mm Hg). 15 However, individuals with diabetes mellitus or stroke were not included in the SPRINT, leaving a knowledge gap regarding whether the lower, the better approach to BP reduction can be applied in individuals with diabetes mellitus.
Herein, we reported our analyses from a large prospective community-based cohort study examining whether BP <120/80 mm Hg were associated with incident CVEs and mortality during ≈7 years of follow-up. We also examined the potential effects of the trajectory of BP during 2 years (2006-2008) on subsequent risk of developing CVEs/mortality after 2008. To minimize the confounding derived from BP-lowering drugs and other cardiovascular disease (CVD)-related clinical conditions, we excluded participants with hypertension and CVDs at recruitment.
Methods

Study Populations
The Kailuan Study is an ongoing longitudinal cohort study begun in 2006. Detailed study design and procedures have been previously described. 16 At baseline (2006) (2007) , a total of 101 510 Chinese individuals (81 110 men and 20 400 women) were enrolled from 11 hospitals affiliated with the Kailuan community in Tangshan (Hebei, China). Subsequently, 3 repeated follow-up examinations were conducted in 2008, 2010, and 2012. All participants were followed up until death or until December 31, 2014, whichever came first. At the baseline and during the biennial follow-up, trained nurses and physicians used all face-to-face survey on demographic characteristics, medical comorbidities information (eg, hypertension, diabetes mellitus, and CVDs) and lifestyle behaviors (eg, smoking status, alcohol consumption, and physical activity) and performed all physical examinations according to the standardized protocol. Questionnaires contained whether the participants used medications for CVDs, hypertension, or diabetes mellitus.
Diabetes mellitus was defined as a fasting blood glucose concentration of ≥7.0 mmol/L, a nonfasting blood glucose concentration of ≥11.1 mmol/L, administration of glucose-lowering medication, or self-reported physician's diagnosis. 17 We identified 9489 individuals with diabetes mellitus by questionnaires and laboratory examinations. To reduce the confounding because of the use of antihypertensive drugs, we further excluded 6160 individuals with hypertension (SBP of ≥140 mm Hg or DBP of ≥90 mm Hg, physician diagnosis of hypertension, or use of antihypertensive drugs). Information on use of antihypertensive drugs and their types (ie, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, calcium channel blockers, α-blockers, polypill, and others) was collected via questionnaires during the surveys. Participants who reported use of any antihypertensive drugs, regardless of their prevalent diseases (ie, CVDs, hypertension, and nephropathy), were excluded in the current analyses.
Considering diabetic participants with CVDs might experience a more complex clinical condition and commonly used renin-angiotensin-aldosterone system blockade or β-blockers, as recommended by the guidelines, [18] [19] [20] we further excluded 159 diabetic participants with physician-diagnosed CVDs. None of the participants in the current analyses used antiplatelet drugs (ie, aspirin) in our study. We also excluded 11 individuals with prevalent cancer at baseline.
Finally, we included 3159 participants in the current analysis, including 831 participants with SBP <120 mm Hg and DBP <80 mm Hg (referred to as BP <120/80 mm Hg in this study) and 2328 participants with SBP of 120 to 139 mm Hg or DBP of 80 to 89 mm Hg (referred to as BP of 120 to 139/80 to 89 mm Hg) were included. Hypotension (SBP <90 mm Hg or DBP <60 mm Hg) was observed in 20 participants.
In a second analysis, we excluded diabetic people who died (n=23) or developed CVEs (n=19) during 2006 to 2008 and individuals who  did not have BP data in 2008 (n=806) to examine the possible association between longitudinal BP trajectory (from 2006 to 2008) and all-cause mortality/CVEs. A flow diagram depicting the stepwise selection process was listed in the online-only Data Supplement.
Similar to previous Chinese national survey, 21 ≈68% of participants in the current study had undiagnosed diabetes mellitus based on laboratory examination in 2006. These participants were unaware of their condition and were untreated. We cannot obtain accurate information on diabetes mellitus duration for these participants. We thus used the diagnosis status (diagnosed versus undiagnosed diabetes mellitus) as a surrogate of diabetes mellitus duration in our analyses.
This study protocol was approved by the ethics committee of the Kailuan Hospital and the Brigham and Women's Hospital in compliance with the guidelines of the World's Association Declaration of Helsinki. All participants gave written informed consent.
Assessment of BP (Exposures)
BP was measured according to the seventh Joint National Committee recommendation 14 every 2 years since the baseline. After being seated for at least 5 minutes in a chair, all participants received at least 2 measures of BP using random 0 sphygmomanometers. The average value of the multiple BP measures was used for further analysis. In the current study, we examined the baseline BP (2006) 
Ascertainment of Myocardial Infarction, Stroke, and Death (Outcomes)
The main outcomes included the all-cause mortality and CVEs (ie, a composite of myocardial infarction and stroke events). Death information was collected from provincial vital statistics offices. Information on physician-diagnosed CVEs was collected in the biennial interview. To further identify potential CVEs, we also investigated discharge lists from the 11 hospitals. All suspected CVEs were ascertained annually via reviewing medical records after recruitment by a committee of 3 experienced physician adjudicators who were blinded to the study design. Incident myocardial infarction was diagnosed according to the World Health Organization's Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) criteria on basis of clinical symptoms and dynamic changes in cardiac enzymes/biomarkers concentrations and electrocardiogram. 22 Stroke was diagnosed according to the World Health Organization criteria, 23 based on signs, symptoms, neuroimages (from computed tomography or magnetic resonance imaging) and other diagnostic reports, as detailed previously.
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Assessment of Potential Covariates
Body mass index (BMI) was calculated as weight (kilograms) divided by height (meters) squared. Smoking status and alcohol-drinking status were divided into 4 categories: never, former, occasional, or daily. Physical activity was assessed by questions on lifestyle behaviors that combined occupational and discretionary physical activities (inactive, moderately active, and vigorously active 25 ). Whole-blood samples were drawn from all participants, generally after an overnight fast and analyzed in the Central Laboratory of Kailuan General Hospital at the same day. The biochemical parameters, including blood glucose, creatinine, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, were measured using an auto-analyzer (Hitachi 747; Hitachi, Tokyo, Japan), as detailed previously. 26 Plasma high-sensitivity C-reactive protein concentrations were measured using a high-sensitivity particle-enhanced immunonephelometry assay (Cias Latex CRP-H, Kanto Chemical Co Inc, Japan). Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.
Statistical Analysis
Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox proportional hazards regression models for the risk of CVEs and all-cause mortality, according to baseline BP status and BP trajectory patterns. The initial models were adjusted for age, sex, and glucose-lowering therapy. The fully adjusted models further included variables that could be associated with both the exposures and outcomes, including smoking and drinking status, BMI, physical activity, education, occupation, estimated glomerular filtration rate, and blood concentrations of fasting blood glucose, triglyceride, highdensity lipoprotein cholesterol, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein.
Given that antidiabetic drugs (eg, metformin) and lipid-lowering drugs (eg, statins) may provide additional effect on CVEs, we conducted several sensitivity analyses by excluding diabetic people receiving glucose-lowering or lipid-lowering therapy or those with hypotension, respectively. Chronic renal failure is common in diabetics and worsens cardiovascular outcomes 28 and individuals with chronic kidney disease stage 4 to 5 may not use angiotensin-converting enzyme inhibitors or angiotensin receptor blockers because of hypotension or hyperkalemia. We thus did a sensitivity analysis by excluding individuals with estimated glomerular filtration rate <30 mL/min/1.73m 2 (chronic kidney disease stage 4-5) to estimate the contribution of BP in diabetics with normal renal function or mildto-moderate renal impairment. To understand whether the possible association between BP trajectories and mortality was attributed to CVDs or hypertension occurred after 2008 (the baseline of the trajectory analysis), we also conducted sensitivity analyses by excluding participants who developed CVDs or hypertension during 2008 to 2012, separately. Because it was unclear whether hypotension in our study was a physiological state or caused by subclinical diseases, we further excluded those with hypotension at baseline in the sensitivity analysis. Given BP <120/80 mm Hg may be caused by chronic illnesses (ie, malignancies) and also be related to a decline in BMI, we sequentially remove individuals developed cancers during follow-up, individuals who had annual weight loss >5% from 2006 to 2008, and individuals with BMI<18.5 kg/m 2 at baseline. Interaction between BP trajectories and sex, BMI, alcohol consumption, diabetic duration for all-cause mortality, and CVEs were also explored.
All statistical tests were 2-sided, and P<0.05 was regarded as significant. Statistical analyses were performed using SAS 9.3 (SAS Institute Inc, Cary, NC).
Results
Individuals with BP <120/80 mm Hg at baseline were more likely to be women, had lower BMI, lower concentrations of triglyceride and high-density lipoprotein cholesterol, and a higher prevalence of smoking and drinking habit and prescription of antidiabetic drugs (Table1).
After a mean of 6.9 years of follow-up, a total of 247 deaths and 177 composite CVEs were documented. One death occurred in hypotensive participants. Baseline BP <120/80 mm Hg was significantly associated with future risk of allcause mortality (HR: 1.46; 95% CI, 1.10-1.93) but not with composite CVEs (HR: 0.83, 95% CI, 0.58-1.19), as compared with BP of 120 to 139/80 to 89 mm Hg (Figure 1) . Similar results were observed in the sensitivity analyses (Table SI in There was also a nonsignificant trend between increase in BP and higher further risk of mortality (Figure 2 ). Excluding diabetic people who developed cancers during follow-up, or (Figure 2 ). The association became stronger when we further excluded individuals prescribed antidiabetic drugs. Individuals with BP elevation from 120 to 139/80 to 89 to ≥140/90 mm Hg had an increased risk of myocardial infarction (HR: 3.34; 95% CI, 1.27-9.28). There was also a nonsignificant but highly plausible tendency that BP elevation was related to further risk of stroke (HR: 1.65; 95% CI, 0.97-2.78; Tables SIII-SV) .
We found a significant interaction between BP trajectories and diabetic duration, but not other potential effect modifiers, for risk of CVEs (P interaction =0.001). The cardiovascular hazard of BP elevation above 140/90 mm Hg was more pronounced in undiagnosed diabetic people, no matter their initial BP <120/80 mm Hg (HR: 3.49; 95% CI, 1.44-8.47) or BP of 120 to 139/80 to 89 mm Hg (HR: 2.51; 95% CI, 1.37-4.61), than in those who were diagnosed previously with longer disease duration ( Figure SIII) .
Discussion
In the current study, we observed that baseline BP <120/80 mm Hg was significantly associated with future risk of allcause mortality but not with CVEs, relative to BP of 120 to 139/80 to 89 mm Hg. The trajectory analysis showed a consistent result. Diabetic people having sustained BP <120/80 mm Hg or a fall in BP from 120 to 139/80 to 89 to <120/80 mm Hg during the first 2 years of the follow-up also had an increased risk of all-cause mortality. An increased risk of Primary cardiovascular outcomes included fatal or nonfatal myocardial infarction events and fatal or nonfatal stroke events. All models were adjusted for age (years), sex, smoking status (never, former, occasional, or daily), glucose-lowering therapy, body mass index (kg/m 2 ), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L), triglyceride (mmol/L), alcohol consumption (never, former, occasional, or daily), educational level (primary, middle or high school, or college/university), occupation (white collar, coalminer, or blue collar), physical activity (inactive, moderately active, or vigorously active), high-sensitivity C-reactive protein (mg/L), fasting blood glucose (mmol/L), and estimated glomerular filtration rate (mL/min/1.73m
2 ).
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CVEs was observed in diabetic people with a rise in BP from 120 to 139/80 to 89 to ≥140/90 mm Hg. Our observation suggest that longitudinal BP trajectories may provide additional information in predicting adverse events besides baseline value in normotensive diabetic patients. Furthermore, our findings indicate that the BP goal based on nondiabetic population or in general population might not be extended to diabetic population. The observed association between persistently low BP and a drop in BP and increased all-cause mortality was independent of the antihypertensive drug effects and previous diseases that would be prescribed antihypertensive drugs such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and β-blockers. Although we did not deliberately exclude individuals using antiplatelet drugs, none of the participants in the current study reported use of antiplatelet drugs (ie, aspirin). This could be because of the exclusion criteriawe excluded diabetic people with CVDs or hypertension at baseline. These participants usually used aspirin, as recommended by American Diabetes Association. 29 The prevalence of antiplatelet drug use could also be underestimated because we collected the data via questionnaires. Nevertheless, the impact of antiplatelet drug use on the observed association between BP and CVEs/mortality could be small. In our sensitivity analysis, exclusion of lipid-lowering drugs, glucose-lowering drugs, or chronic kidney disease stage 4 to 5 generated similar results. This would minimize the potential effects of these commonly used medications on CVDs/ mortality. Hence, our results may reflect the real relationship between BP and adverse events.
BP <120/80 mm Hg seemed to be common in diabetic people with lower BMI, lower concentrations of triglyceride and high-density lipoprotein cholesterol, a higher prevalence of smoking and drinking habit, and administrate of glucose-lowering drugs. This suggested a poor health status or an underlying illness which could be associated with increased mortality risk. Further excluding participants who developed CVDs, hypertension, or cancers during follow-up generated similar significant results, suggesting that the increased hazards might be because of a poor health conditions or deterioration from subclinical diseases in these participants, not necessarily a change in atherosclerotic burden over time. Diabetic people may suffer other diseases (eg, infection and amyloidosis) that result in impaired cardiac output and abnormal vasodilatation, exhibiting a decrease in BP. [30] [31] [32] Therefore, a relatively low BP may reflect the progression toward complex diabetic comorbidities and mortality.
Previous studies generally considered the initial or achieved BP (a single point in time) as a risk predictor. The potential effect of change in BP over time was not well characterized in these studies. This may pose a research problem whether the BP of 120 to 139/80 to 89 mm Hg (as called prehypertension previously) itself is harmful or just because it develops subsequent hypertension over time. We found that the cardiovascular hazard was pronounced in diabetic people who developed hypertension at 2008. Even in people with initial low BP, there remains a similar tendency albeit without significance. This suggests that the BP elevation over time could be relevant to further CVEs, which could be caused by shear stress abnormalities and endothelium disorder, followed by vessel impairment in a high BP. [33] [34] [35] Interestingly, BP elevation above 140/90 mm Hg seemed more deleterious in individuals with undiagnosed diabetes mellitus than in individuals diagnosed previously, no matter of their initial BP. It was probably because of chance. Another interpretation is that previously diagnosed diabetic participants commonly used glucose-lowering drugs but undiagnosed individuals not. Some antidiabetic drugs (eg, metformin) provide additional cardioprotective effect and somewhat offset the adverse impact of elevated BP. 36 This notion was supported by a sensitivity analysis in which the cardiovascular hazard caused by BP elevation became stronger after exclusion of antidiabetic drugs. Our findings were consistent with a recent study, in which individuals with increases in BP (modest-increasing and elevated-increasing) during a 25-year period had the highest risk of subclinical atherosclerosis compared with other trajectory groups. 37 The majority of these participants had an initial BP within a range of prehypertension. Together with this study, we suggest that not only is the achieved BP important, but longitudinal change in BP predicts high risk that are compatible or beyond the baseline value. Therefore, it is important to monitor longitudinal patterns of change in BP in clinical practice.
The strength of the current study included that using longitudinal data from a large, community-based cohort study with ≈7 years of follow-up, which allowed us to more realistically understand the association between natural process of BP and diabetic prognosis. Several limitations of our study deserve mention. First, although the current data derived from a large ongoing cohort including 101 510 adults, the sample size was relatively small, especially for women. We thus did not have enough statistical power to detect smallto-modest sex difference. Second, the participants in our study were relatively young or with low BMI. This could be explained by the fact that the majority of our diabetic participants were newly detected and had not developed obvious complications. Our results may not be able to generalize to elderly diabetic people or those with a complex clinical condition (ie, obesity, CVDs, and nephropathy). All participants were residents of the Kailuan community in Tangshan (Hebei, China) and were primarily of Northern Han Chinese ethnicity. Further studies are needed to be conducted in diabetic population of other ethnic origins. Third, we did not measure hemoglobin A1c at baseline because of its high cost as a screening test in general population. Fourth, the followup period was relatively short for studying BP trajectory patterns. We did not include BP measures at 2010 and 2012 for the trajectory analysis because of lack of statistical powerfew incident CVEs or deaths occurred during 2012 to 2014. However, the sensitivity analysis by excluding those who developed hypertension during 2008 to 2012 generated similar results. Fifth, although we minimized the drug effects on CVDs, residual confounding from nonpharmacological factors cannot be completely excluded. Individuals with diabetes mellitus are encouraged to reduce weight, quit smoking, and restrict intake of sugar and salt. These behaviors may favorably modify BP. Finally, we did not collect information on specific causes of death.
Perspectives
The spontaneous trajectory patterns of BP in participants with diabetes mellitus were associated with alerted risks of development of CVEs or all-cause mortality. Dynamic BP observation may provide additional predictive information compared with the measures at one single time. Our findings need to be replicated in further studies with longer follow-up and larger sample size, including a large proportion of women and participants with different ethnicity. If confirmed, the clinical judgment with respect to the safe BP goal should consider the within-people change for each individual with diabetes mellitus. 
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• Longitudinal blood pressure trajectories were significantly associated with adverse events in normotensive diabetic people after minimizing the drug effects on cardiovascular diseases. Persistently lower blood pressure and a spontaneous drop in blood pressure were significantly associated with future risk of all-cause mortality, whereas development of incident hypertension increased the risk of cardiovascular events.
What Is Relevant?
• Although limited sample size because of strict inclusion criteria and nonrandomized allocation made our study underpowered to determine an optimal blood pressure level against adverse health outcomes in the diabetic population, we still suggest that the BP goal in nondiabetic population or in general population might not be extended to diabetic population. Abbreviations: BP, blood pressure; HR, hazard ratios; CI, confidence interval.
